MedPath
Found 65 clinical trials|View Analysis
Sort by:

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Phase 3
Completed
Conditions
Lower Ureteric Stones
Interventions
Drug: Tamsulosin
Drug: Cetirizine
Combination Product: Cetirizine + Tamsulosin
Other: Placebo
First Posted Date
2024-12-31
Last Posted Date
2024-12-31
Lead Sponsor
South Valley University
Target Recruit Count
480
Registration Number
NCT06754410
Locations
🇪🇬

Qena university hospital, Qena, Egypt

Open-Label Extension Study for Subjects With H1 Antihistamine Refractory Chronic Spontaneous Urticaria Completing Study AK006-001

Phase 1
Conditions
Chronic Spontaneous Urticaria
Interventions
Drug: AK006 IV
First Posted Date
2024-08-29
Last Posted Date
2024-11-27
Lead Sponsor
Allakos Inc.
Target Recruit Count
60
Registration Number
NCT06577116
Locations
🇺🇸

Site 601-013, Greenfield, Wisconsin, United States

🇺🇸

Site 601-004, Birmingham, Alabama, United States

🇺🇸

Site 601-014, Bakersfield, California, United States

and more 10 locations

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Phase 3
Completed
Conditions
Mucopolysaccharidosis Type 1
Interventions
Biological: Laronidase
Drug: Antihistamine
Drug: Antipyretic
First Posted Date
2024-05-09
Last Posted Date
2024-08-06
Lead Sponsor
Cinnagen
Target Recruit Count
12
Registration Number
NCT06406153
Locations
🇮🇷

Loghman Hospital, Tehran, Iran, Islamic Republic of

🇮🇷

Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad, Iran, Islamic Republic of

🇮🇷

Growth and Development Research Center, Childrens Medical Center, Tehran, Iran, Islamic Republic of

and more 1 locations

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Phase 2
Recruiting
Conditions
Chronic Spontaneous Urticaria
Interventions
Biological: Placebo
Biological: LP-003
Biological: Omalizumab
First Posted Date
2024-01-29
Last Posted Date
2024-02-22
Lead Sponsor
Longbio Pharma
Target Recruit Count
200
Registration Number
NCT06228560
Locations
🇨🇳

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

🇨🇳

The First Affiliated Hospital of China Medical University, Beijing, Beijing, China

and more 13 locations

First-generation OTC Antihistamine Use and Voice Function: A Preliminary Study

Early Phase 1
Completed
Conditions
Voice Disorder Due to Iatrogenic Factor
Interventions
Drug: Chlor-Trimeton.
First Posted Date
2023-05-15
Last Posted Date
2024-04-24
Lead Sponsor
Auburn University
Target Recruit Count
8
Registration Number
NCT05858216
Locations
🇺🇸

Department of Speech, Language & Hearing Sciences, Auburn University, Auburn, Alabama, United States

Acupuncture for Nasal Congestion in Allergic Rhinitis

Not Applicable
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: Antihistamine nasal spray
Other: Acupuncture
First Posted Date
2023-02-02
Last Posted Date
2024-06-25
Lead Sponsor
Johanna Maria Vermeulen
Target Recruit Count
11
Registration Number
NCT05709977
Locations
🇳🇱

Mermaid Medicine®, Den Haag, Zuid-Holland, Netherlands

Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Recruiting
Conditions
Allergic Rhinitis
Interventions
Drug: concomitant intranasal antihistamine and corticosteroid
First Posted Date
2023-02-01
Last Posted Date
2023-02-01
Lead Sponsor
Gachon University Gil Medical Center
Target Recruit Count
240
Registration Number
NCT05708157
Locations
🇰🇷

Gachon University Gil Medical Center, Incheon, Korea, Republic of

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Phase 3
Recruiting
Conditions
Chronic Spontaneous Urticaria
Interventions
Drug: LOU064 (blinded)
Drug: placebo
First Posted Date
2023-01-10
Last Posted Date
2024-12-24
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT05677451
Locations
🇺🇸

Kern Research, Bakersfield, California, United States

🇺🇸

Allergy and Asthma Medical Group and Research Center, San Diego, California, United States

🇺🇸

Pediatric Dermatology of Miami at the Pediatric CoE, Coral Gables, Florida, United States

and more 10 locations

Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection

Recruiting
Conditions
COVID-19
Interventions
Drug: Antihistamine
Drug: Amantadine
First Posted Date
2022-08-17
Last Posted Date
2024-04-26
Lead Sponsor
Consorci Sanitari de Terrassa
Target Recruit Count
170000
Registration Number
NCT05504057
Locations
🇪🇸

Hospital de Terrassa, Terrassa, Barcelona, Spain

🇪🇸

Hospital of Terrassa, Terrassa, Barcelona, Spain

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Phase 1
Recruiting
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
First Posted Date
2022-04-08
Last Posted Date
2024-12-27
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
200
Registration Number
NCT05319730
Locations
🇺🇸

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927), Tucson, Arizona, United States

🇺🇸

Hematology-Oncology Associates of Central NY, P.C. ( Site 4925), East Syracuse, New York, United States

🇧🇷

Liga Norte Riograndense Contra o Câncer ( Site 4303), Natal, Rio Grande Do Norte, Brazil

and more 50 locations
© Copyright 2025. All Rights Reserved by MedPath